Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid | Spain
Our laboratory is interested in understanding the molecular events implicated in the development of K-RAS driven lung and pancreatic cancers, two of the tumor types with worse prognosis. In addition, we are using a new generation of genetically engineered mouse tumor models to identify, and subsequently validate, targets of therapeutic value with the ultimate goal of establishing combination therapies that can be translated to the clinic in the forthcoming future.
Keywords: Ras oncogenes / MAP kinase pathway / mouse tumor models / therapeutic targets
Subject area(s): Cell Cycle | Molecular Medicine | Signal Transduction